Claims
- 1. A compound selected from the group of 1,2-, 1,3-, and 1,4-disubstituted piperidine of Formula I ##STR43## wherein X is an ethylene chain or a 1,2-benzo ring;
- Y is a carbonyl group or -CH.sub.2 -, with the proviso that Y is carbonyl only when X is a 1,2-benzo ring;
- R.sup.1 is selected from hydrogen or C.sub.1-4 alkyl; and
- Z is an R.sup.2 -, R.sup.3 - disubstituted diazine bonded through a carbon atom thereof and selected from pyrimidine, pyridazine and pyrazine, with R.sup.2 and R.sup.3 being independently chosen from hydrogen,lower (C.sub.1-4) alkyl, lower alkoxy, lower alkylthio, cyano, trifluoromethyl, pentafluorethyl, and halogen and connected at carbon atoms of the diazine;
- and the pharmaceutically acceptable acid addition salts thereof.
- 2. A compound of claim 1 wherein X is ethylene and R.sup.1 is hydrogen.
- 3. A compound of claim 1 wherein R.sup.2 and R.sup.3 are independently selected from hydrogen, halogen, and trifluoromethyl.
- 4. A compound of claim 2 wherein R.sup.2 and R.sup.3 are independently selected from hydrogen, halogen, and trifluoromethyl.
- 5. The compound of claim 1, 2-[[1-(2-pyrimidinyl)-4-piperidinyl]methyl]-1H-isoindole-1,3-(2H)-dione.
- 6. The compound of claim 1, 1-[[1-(2-pyrimidinyl)-4-piperidinyl)]methyl]-2-pyrrolidinone.
- 7. The compound of claim 1, 1-[[1-(2-chloro-4-pyrimidinyl) -4-piperidinyl]-methyl]-2-pyrrolidinone.
- 8. The compound of claim 1, 1-[[1-(4-chlro-2-pyrimidinyl) -4-piperidinyl]methyl]-2-pyrrolidinoine.
- 9. The compound of claim 1, 1-[[1-(6-chloro-2pyrazinyl)-4--piperidinyl]-methyl]-2-pyrrolidinone.
- 10. The compound of claim 1, 1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]methyl]-2-pyrrolidinone.
- 11. The compound of claim 1, 1-[[1-(2-pyrimidinyl)-3-piperidinyl]methyl]-2-pyrrolidinone.
- 12. The compound of claim 1, 1-[[1-2-pyrimidinyl)-2-piperidinyl]methyl]-2-pyrrolidinone.
- 13. The compound of claim 1, 1-[[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]-methyl]-2-pyrrolidinone.
- 14. The compound of claim 1, 1-[[1-(5-fluoro-4-(methylthio)-2-pyrimidinyl]-4-piperidinyl]methyl]-2pyrrolidininone.
- 15. The compound of claim 1,1-[[1-(5-fluro-2-pyrimidinyl)-4-piperidinyl]-methyl]-2-pyrrolidinone.
- 16. The compound of claim 1, 1-[[1-(2,6-dichloro-4-pyrimidinyl4-piperid815 inyl]-methyl]-2-pyrrolidinone.
- 17. The compound of claim 1, 1-[[1-(4,6-dichloro-2-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
- 18. The compound of claim 1, 1-[[1-(6-chloro-4-pyrimidinyl)-b 4-piperidinyl]methyl]-2-pyrrolidinone.
- 19. The compound of claim 1, 1-[[1-(2-chloro-6-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
- 20. The compound of claim 1, 1-[[1-(4-chloro-6-methyl-2-pyrimidinyl)4-piperidinyl]methyl]-2-pyrrolidinone.
- 21. The compound of claim 1, 1[[1]-(5-bromo-2-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
- 22. The compound of claim 1, 1-[[1-(5-chloro-2-pyrimidinyl) -4-piperidinyl]methyl]-2-pyrrolidinone.
- 23. The compound of claim 1, 1[[-(5-iodo-2-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
- 24. The compound of claim 1, 1-[[1-(6-chloro-2-(methylthio)-4-pyrimidinyl]-4-piperdinyl]methyl]-2-pyrrolidinone.
- 25. The compound of claim 1, 1-[[1-(5,6-dichloro -4-pyridazinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
- 26. The compound of claim 1, 1-[[1-(5-bromo-2-chloro-4-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
- 27. The compound of claim 1, 1-[[1-(2-methyoxy-4-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
- 28. The compound of claim 1, 4-]4-(2-oxopyrrolidin-1-yl)methyl]-1-piperidinyl]-2-pyrimidine-carbonitrile.
- 29. The compound of claim 1, 1-[[1-]2-(pentafluoroethyl) -4-pyrimidinyl]-4-piperidinyl]methyl]2-pyrrolidinone.
- 30. The compound of claim 1, 1-[[1-[5-chloro-2-(trifluromethyl)-4-pyrimdinyl]-4-piperidinyl]methyl]2-pyrrolidinone.
- 31. The compound of claim 1, 1-[[1-[2,6-bis-trifluoromethyl)-4-pyurimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone.
- 32. The compound of claim 1, 1-[[1-(6-chloro-3-pyridazinyl) -4-piperidinyl]methhyl]-2-pyrrolidinone.
- 33. The method for enhancing cerebral function in a mammal in need of such treatment which comprises systemic administration to the mammal of an effective dose a compound claimed in claim 1.
- 34. The method for treating a disorder in a mammal in need of such treatment, the disorder selected from the group consisting of dementia, amnesia, failing memory, learning disability, mild retardation, dyslexia, aphasia, and Tourette's syndrome; the treatment comprising systemic administration to the mammal of an effective dose of a compound claimed in claim 1.
- 35. A compound of claim 1 comprising a 1,4-disubstituted piperidine of formula I.
- 36. A pharmaceutical composition for the enhancement of cerebral function comprising a pharmaceutical carrier and a compound according to claim 1.
CROSS REFERENCE TO RELATED APPLICATION
This is a continuation-in-part application of Ser. No. 868,468 filed May 30, 1986, now abandoned, which is itself a continuation-in-part application of Ser. No. 753,006 filed July 8, 1985, and now abandoned.
US Referenced Citations (4)
Non-Patent Literature Citations (2)
Entry |
Butler, et al., J. Med. Chem., 27, pp. 684-691 (1984) (3/13). |
Malawska, et al., Polish Journal of Pharmacology, 34, pp. 373-382 (1982) (5/4). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
868468 |
May 1986 |
|
Parent |
753006 |
Jul 1985 |
|